WARRINGTON, Pa., March 26, 2012 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) will report fourth quarter 2011 results on Thursday, March 29, 2012 before the open of the U.S. financial markets. Discovery Labs will also host a conference call at 10:00 a.m. ET on the same day to discuss its financial position and recent operational highlights. A question-and-answer session will follow Discovery Labs' remarks.
Participants are encouraged to access this audio webcast through a live broadcast on the Company's website at www.discoverylabs.com. It is recommended that participants log onto the audio webcast at least 15 minutes prior to the call. The Internet broadcast will be available for up to 90 days after the call at the Company's website.
The call in number is (877) 215-0093. The international call in number is (706) 679-3237. A replay of the conference call will be available two hours after the call's completion and remain available through April 29, 2012. The replay number to hear the conference call is (855) 859-2056 or (404) 537-3406. The passcode is 64962880.
About Discovery Labs
Discovery Laboratories, Inc. is a specialty biotechnology company with one focus – to advance a new standard in respiratory critical care. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, lyophilized, and aerosolized dosage forms. Discovery Labs is also developing its proprietary drug delivery technologies to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs believes that its proprietary technologies make it possible, for the first time, to develop a significant pipeline of products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.Discoverylabs.com.
Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Examples of such risks and uncertainties are described in Discovery Labs' filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Except as otherwise required by law, Discovery Labs undertakes no obligation to update or revise any forward-looking statements.